# A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia

> **NCT02412917** · PHASE3 · TERMINATED · sponsor: **ContraVir Pharmaceuticals, Inc.** · enrollment: 237 (actual)

## Conditions studied

- Shingles
- Herpes Zoster
- Postherpetic Neuralgia

## Interventions

- **DRUG:** FV-100
- **DRUG:** valacyclovir

## Key facts

- **NCT ID:** NCT02412917
- **Lead sponsor:** ContraVir Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-06
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 237 (ACTUAL)
- **Last updated:** 2017-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02412917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02412917, "A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02412917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*